Quiviviq and Breastfeeding
Quiviviq (daridorexant) can be used during breastfeeding with infant monitoring for sedation, as it transfers into breast milk in very low amounts (relative infant dose <1% of maternal dose). 1
Key Evidence from FDA Label
The FDA label provides the most authoritative guidance for this medication 1:
- Daridorexant is present in human breast milk in low amounts
- In a clinical lactation study of 10 healthy lactating women receiving a single 50 mg dose:
- Mean daily infant dose: 0.0016 mg/kg
- Relative infant dose (RID): 0.22% of maternal weight-adjusted dose
- 87% of total drug in milk detected by 24 hours post-dose
- Steady-state levels expected to be similar to single-dose levels
Clinical Recommendation
Breastfeeding can continue while taking Quiviviq, but infants must be monitored for excessive sedation. 1
Monitoring Requirements
The breastfed infant should be observed for:
- Excessive sedation or drowsiness
- Poor feeding
- Any signs of central nervous system depression
If these signs occur, contact a medical professional immediately.
Risk-Benefit Context
The decision framework should weigh:
- Developmental and health benefits of breastfeeding (substantial and well-established) 2
- Mother's clinical need for insomnia treatment (untreated insomnia affects maternal function and infant care)
- Potential adverse effects on the infant (theoretical risk given very low exposure)
- Effects on milk production (no data suggesting impact)
Why This Medication Is Relatively Safe
The extremely low RID of 0.22% is well below the generally accepted safety threshold of 10% for medication use during lactation 3. This means the infant receives less than 1% of the weight-adjusted maternal dose through breast milk—a negligible amount by standard lactation pharmacology principles.
Important Caveats
- No long-term safety data exists on effects in breastfed infants 1
- The pharmacokinetic study was conducted in healthy women; real-world variability may exist
- Individual infant factors (prematurity, age, hepatic/renal function) could theoretically affect drug handling, though oral bioavailability and the minuscule dose make clinically significant effects unlikely
Practical Guidance
- Take the medication at bedtime as prescribed
- Breastfeed before taking the dose when possible to minimize infant exposure
- Watch the infant closely during the first few days of maternal treatment
- Do not discontinue breastfeeding unnecessarily—the benefits of continued breastfeeding likely outweigh the minimal theoretical risk 2
The AAP guideline emphasizes that most maternal medications are compatible with breastfeeding, and comprehensive resources like LactMed should be consulted 2. The available evidence for daridorexant supports compatibility with appropriate infant monitoring.